ClinicalTrials.gg
Active, not recruitingNCT06602479AURORAUpdated Oct 28, 2026

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

A Phase 2 interventional study of MEDI0618 and Placebo in Migraine, sponsored by AbbVie. Active, not recruiting at 71 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AbbVie · Phase 2, Interventional, and Prevention

Updated Oct 28, 2026Now Active, not recruitingPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Migraine Disorders by AbbVie — 9 open to participants now, 13 under way, 7 of them phase 3. Migraine Disorders · AbbVie.

Enrollment
28th of 41
309 · median 524
Started
2024
with 4 others
Phase 2
3 of 55
none open now
Primary completion
2027-02
later than 1 of 12 live
Registered
49th of 55
by date

Among the 55 studies in Migraine Disorders by AbbVie, this one is the 28th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2024, is one of 3 in phase 2, reaches primary completion later than 1 of the 12 other live ones, and was the 49th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

9 of the 55 studies in Migraine Disorders by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Migraine Disorders by AbbVie, or all of them as a file.
02

Study summary

The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

Read the detailed description

This Phase 2, randomised, multicentre, parallel-group treatment, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of subcutaneous (SC) MEDI0618 in participants with episodic migraine.

The study includes a cohort of participants who have a history of unsuccessful treatment with >= 2 small molecule migraine preventive treatments from different classes per investigator's judgement and are eligible to receive anti-calcitonin gene-related peptide (aCGRP) therapy but have not yet done so (aCGRP-naïve [aCGRP-N]); The study also includes a smaller cohort of participants who have failed one or more aCGRP therapies (aCGRP-IRs) used for preventative treatment and have a history of unsuccessful treatment with >= 2 small molecule migraine preventive treatments from different classes.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • MEDI0618
  • Episodic Migraine
  • Migraine headache day(s) - MHD
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years of age
  • Weight ≥ 40 kg and ≥ 18.0 kg/m2.
  • History of migraine headaches with or without aura, with migraine onset at ≤ 50 years of age and for at least 12 months prior to screening.
  • At least 12 MHDs over the last 3 months prior to screening.
  • Participants must fulfil the following criteria for migraine in prospectively collected baseline information during the 4 consecutive weeks of baseline migraine headache data collection prior to Day 1: (a) ≥ 4 and ≤ 14 MHDs per month. (b) On ≥ 4 days, fulfils any of the following criteria: (i) migraine without aura; (ii) migraine with an aura symptom accompanied or followed by a headache within 60 minutes; (iii) probable migraine; (iv) recurrent attacks that do not match ICHD criteria for migraine but successfully respond to migraine-specific medication.
  • Participants who fulfil criteria for MOH are eligible for this study.
  • History of unsuccessful treatment with ≥ 2 small molecule migraine preventive treatments from different classes (a) aCGRP-N participants are eligible to receive an aCGRP therapy but must have not yet received aCGRP therapy for acute or preventive treatment at any time. (b) aCGRP-IR participants must have tried and have failed at least one aCGRP therapy used for preventive treatment.
  • Participants must be able to distinguish migraine headaches from tension-type headaches.
  • Female participants who are not pregnant and do not plan to become pregnant during the study, are not lactating, or are of nonchildbearing potential. FOCBP who are sexually active with a non-sterilised male partner must use adequate consisting of one highly effective methods of contraception throughout the study. FOCBP must agree to comply with protocol specified guidance for safe administration of MEDI0618. FOCBP must refrain from egg donation and in vitro fertilisation from the time of signing the ICF, throughout the study, and for 10 weeks after the last administration of product (IP).

Exclusion criteria

Exclusion Criteria:

  • History of migraine sub-types including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and basilar-type migraine
  • History of headache other than migraine within 3 months prior to screening.
  • History of severe or ongoing allergy/ reactions or history of hypersensitivity to immunisations or immunoglobulins.
  • History of any significant psychiatric disorder which could be detrimental to participant safety or could compromise study data interpretation.
  • Presence of any illness, such as cardiovascular, neurologic (except for non-exclusionary headaches in participants with migraine), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, or endocrine disease or disorder.
  • History of cancer within 5 years of screening, or between screening and randomisation, with the exception of non- basal cell carcinoma of the skin, carcinoma in situ of the cervix, or non-progressive prostate cancer.
  • Known history of drug or alcohol abuse within 1 year of screening or positive test for drugs of abuse or alcohol at screening or at Day -1.
  • History of > 450 msec (> 470 msec for participants aged ≥ 65 years) associated with other medications that required discontinuation of that medication.
  • Congenital long or short QT syndrome.
  • History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication are permitted.
  • Use of migraine preventive medications within 30 days or 5 half-lives (whichever is longer) prior to screening and throughout the study
  • For aCGRP-N participants only: prior use of an aCGRP therapy for acute or preventive treatment.
  • Use of opioids or barbiturate containing analgesic > 2 times/month on average in the 6 months prior to screening for the treatment of pain (opioid administration in an emergency setting may be an exception).
  • Use of botulinum toxin (e.g., Botox ®, Dysport®, Jeuveau™, Myobloc®, Xeomin®) for migraine or for any other medical or cosmetic reasons requiring injections in the head, face, or neck during the 4 months prior to screening.
  • Use of an intervention or device (eg, scheduled nerve block, transcranial magnetic stimulation) for treatment of migraine within 2 months of screening.
  • Use of prescription or non-prescription, non-biologic drugs, including vitamins and herbal and dietary supplements, within 7 days or 5 half-lives (whichever is longer) prior to screening and throughout the study unless the medication will not interfere with the study procedures or compromise participant safety; the dose and regimen must have been stable for at least 3 months prior to screening and must remain stable throughout the study.
  • Requires treatment with another biological therapeutic agent including IV immunoglobulin treatment during the course of the study. Prior use of therapeutic antibodies is allowed if that use was > 5 half-lives of the intervention or 3 months prior to screening, whichever is longer.
  • Therapeutic vaccines are permitted during the study, but ideally, should be administered > 30 days prior to randomisation and inactivated vaccinations (eg, inactive influenza, COVID-19) should be administered > 14 days prior to randomisation.
  • Participation in another clinical study with an IP, including an experimental vaccine, or device, within 5 half-lives of the intervention or 3 months prior to screening, whichever is longer.
  • Known hypersensitivity to MEDI0618 or any of the of the product.

Other protocol defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    aCGRP-N_MEDI0618 (Dose A)

    In the aCGRP-N cohort, 128 participants will be randomised on a 1:1 basis to receive MEDI0618 Dose A or placebo. After 104 participants total have been randomised, 3 other dose arms with MEDI0618 will be initiated and include 24 participants each.

    Drug: MEDI0618

  • Placebo comparator
    aCGRP-N_Placebo

    In the aCGRP-N cohort, 128 participants will be randomised on a 1:1 basis to receive MEDI0618 Dose A or placebo. After 104 participants total have been randomised, 3 other dose arms with MEDI0618 will be initiated and include 24 participants each.

    Drug: Placebo

  • Experimental
    aCGRP-N_MEDI0618 (Dose B)

    After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.

    Drug: MEDI0618

  • Experimental
    aCGRP-N_MEDI0618 (Dose C)

    After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.

    Drug: MEDI0618

  • Experimental
    aCGRP-N_MEDI0618 (Dose D)

    After 104 participants total have been randomised on Dose A and placebo arms, MEDI0618 will be initiated and include 24 participants each on active dose arm.

    Drug: MEDI0618

  • Experimental
    aCGRP-IR_MEDI0618 (Dose A)

    In the aCGRP-IR cohort there will be 1:1 randomisation of participants (50 to MEDI0618 and 50 to placebo).

    Drug: MEDI0618

  • Placebo comparator
    aCGRP-IR_Placebo

    In the aCGRP-IR cohort there will be 1:1 randomisation of participants (50 to MEDI0618 and 50 to placebo).

    Drug: Placebo

Interventions

  • MEDI0618 per protocol

  • DrugPlacebo

    Volume-matched placebo for all arms

06

What researchers measure

Primary outcomes

  1. Efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine

    Change from baseline in mean monthly MHDs across the 12-week treatment period.

    Time frame: Up to approximately Week 12

  2. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately Day 141

Secondary outcomes

  1. Efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine as proportion of patients

    Participants with at least 50% reduction from baseline in number of mean monthly MHDs across the 12-week treatment period

    Time frame: Up to approximately Week 12

  2. Effect of repeat doses of MEDI0618 on disability caused by migraine headaches

    Change in MIDAS score from baseline to end of treatment period and to follow-up.

    Time frame: Up to approximately Day 141

  3. Effect of repeat doses of MEDI0618 on disability caused by migraine headaches

    Change in HIT-6 score from baseline throughout the treatment period and to follow-up

    Time frame: Up to approximately Day 141

  4. Effect of repeat doses of MEDI0618 on the severity of migraine headaches

    Change in number of mean monthly moderate or severe MHDs from 4-week baseline across treatment period

    Time frame: Up to approximately Week 12

  5. Effect of repeat doses of MEDI0618 on the severity of migraine headaches

    Change in number of mean monthly moderate or severe headache days from 4-week baseline across the 12-week treatment period

    Time frame: Up to approximately Week 12

  6. Effect of repeat doses of MEDI0618 on the severity of migraine headaches

    Change in mean monthly frequency of use of permitted acute treatment to abort migraine headaches from 4-week baseline across the 12-week treatment period

    Time frame: Up to approximately Week 12

07

Study locations

71 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Feb 2027, 28 months after the start.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 28 months is above that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2026 → Feb 2027 and completion May 2027 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Sep 19, 2024
StartActual
Oct 7, 2024
Primary completionEst.
Feb 2027was Dec 2026
CompletionEst.
Feb 2027was May 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 28, 2026
Sites
21 sites added, 4 sites removed
Show 21 added (21 United States)
  • Rehabilitation and Neurological Services · Huntsville, United States
  • Gilbert Neurology · Gilbert, United States
  • 21st Century Neurology · Phoenix, United States
  • M3 Wake Research - Newport Beach · Los Angeles, United States
  • Excell Research · Oceanside, United States
  • Neurology Offices of South Florida - Boca Raton · Boca Raton, United States
  • AppleMed Research Group · Miami, United States
  • Well Pharma Medical Research · Miami, United States
  • Sensible Healthcare · Ocoee, United States
  • Albuquerque Clinical Trials · Albuquerque, United States
  • Dent Neurologic Institute - Amherst · Amherst, United States
  • New York Cancer and Blood Specialists - Port Jefferson Station · Commack, United States
  • Upstate Clinical Research Associates · Williamsville, United States
  • Lynn Institute of Oklahoma City · Oklahoma City, United States
  • Lehigh Center for Clinical Research · Allentown, United States
  • Frontier Clinical Research - Smithfield · Smithfield, United States
  • Chattanooga Medical Research · Chattanooga, United States
  • M3 Wake Research - Chattanooga · Chattanooga, United States
  • Future Search Trials of Dallas · Dallas, United States
  • Highland Clinical Research · Salt Lake City, United States
  • Seattle Clinical Research Center · Seattle, United States
Show 4 removed
  • Tennessee Valley Neurological Associates PC · Huntsville, United States
  • Norton Neuroscience Institute - Headache Clinic · Louisville, United States
  • Modern Migraine, MD · New York, United States
  • Fachuebergreifende Gemeinschaftspraxis Dr. med. Joachim Springub & Wolfgang Schwarz · Westerstede, Germany
Oct 28, 2026
Primary completion
Dec 18, 2026→Feb 2027
Oct 28, 2026
Study completion
May 7, 2027→Feb 2027
Oct 28, 2026
Enrollment
488 (estimated)→309 (actual)
Oct 28, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedFemale participants who are not pregnant and do not plan to become pregnant during the study, are not lactating, or are of nonchildbearing potential. FOCBP who are sexually active with a non-sterilised male partner must use adequate contraception consisting of twoone highly effective methods of contraception throughout the study. FOCBP must agree to comply with protocol specified guidance for safe administration of MEDI0618. FOCBP must refrain from egg donation and in vitro fertilisation from the time of signing the ICF, throughout the study, and for 10 weeks after the last administration of investigational product (IP).
Oct 28, 2026
Primary outcomes
1 time frame changed, 1 added, 1 description edited
What changed in the outcomes
  • AddedNumber of Participants with Adverse Events (AEs)Time frame: Up to approximately Day 141
  • Time frameEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraineWeek 9 to Week 12 → Up to approximately Week 12
  • DescriptionEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine: how it is measured was reworded
Oct 28, 2026
Secondary outcomes
6 time frame changed, 4 description edited
What changed in the outcomes
  • Time frameEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine as proportion of patientsWeek 9 to Week 12 → Up to approximately Week 12
  • Time frameEffect of repeat doses of MEDI0618 on disability caused by migraine headachesDay 1 to Day 85 and to Day 141 → Up to approximately Day 141
  • Time frameEffect of repeat doses of MEDI0618 on disability caused by migraine headaches#2Day 1, Day 29, Day 57 and Day 85 and to Day 141 → Up to approximately Day 141
  • Time frameEffect of repeat doses of MEDI0618 on the severity of migraine headachesWeek 9 to Week 12 → Up to approximately Week 12
  • Time frameEffect of repeat doses of MEDI0618 on the severity of migraine headaches#2Week 9 to Week 12 → Up to approximately Week 12
  • Time frameEffect of repeat doses of MEDI0618 on the severity of migraine headaches#3Week 9 to Week 12 → Up to approximately Week 12
  • DescriptionEffect of repeat doses of MEDI0618 on the severity of migraine headaches: how it is measured was reworded
  • DescriptionEffect of repeat doses of MEDI0618 on the severity of migraine headaches#2: how it is measured was reworded
  • DescriptionEffect of repeat doses of MEDI0618 on the severity of migraine headaches#3: how it is measured was reworded
  • DescriptionEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine as proportion of patients: how it is measured was reworded
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Active, not recruiting
    21 sites added, 4 sites removed
    Show 21 added (21 United States)
    • Rehabilitation and Neurological Services · Huntsville, United States
    • Gilbert Neurology · Gilbert, United States
    • 21st Century Neurology · Phoenix, United States
    • M3 Wake Research - Newport Beach · Los Angeles, United States
    • Excell Research · Oceanside, United States
    • Neurology Offices of South Florida - Boca Raton · Boca Raton, United States
    • AppleMed Research Group · Miami, United States
    • Well Pharma Medical Research · Miami, United States
    • Sensible Healthcare · Ocoee, United States
    • Albuquerque Clinical Trials · Albuquerque, United States
    • Dent Neurologic Institute - Amherst · Amherst, United States
    • New York Cancer and Blood Specialists - Port Jefferson Station · Commack, United States
    • Upstate Clinical Research Associates · Williamsville, United States
    • Lynn Institute of Oklahoma City · Oklahoma City, United States
    • Lehigh Center for Clinical Research · Allentown, United States
    • Frontier Clinical Research - Smithfield · Smithfield, United States
    • Chattanooga Medical Research · Chattanooga, United States
    • M3 Wake Research - Chattanooga · Chattanooga, United States
    • Future Search Trials of Dallas · Dallas, United States
    • Highland Clinical Research · Salt Lake City, United States
    • Seattle Clinical Research Center · Seattle, United States
    Show 4 removed
    • Tennessee Valley Neurological Associates PC · Huntsville, United States
    • Norton Neuroscience Institute - Headache Clinic · Louisville, United States
    • Modern Migraine, MD · New York, United States
    • Fachuebergreifende Gemeinschaftspraxis Dr. med. Joachim Springub & Wolfgang Schwarz · Westerstede, Germany
    Primary completion Dec 18, 2026→Feb 2027
    Study completion May 7, 2027→Feb 2027
    Enrollment 488 (estimated)→309 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedFemale participants who are not pregnant and do not plan to become pregnant during the study, are not lactating, or are of nonchildbearing potential. FOCBP who are sexually active with a non-sterilised male partner must use adequate contraception consisting of twoone highly effective methods of contraception throughout the study. FOCBP must agree to comply with protocol specified guidance for safe administration of MEDI0618. FOCBP must refrain from egg donation and in vitro fertilisation from the time of signing the ICF, throughout the study, and for 10 weeks after the last administration of investigational product (IP).
    Primary outcomes 1 time frame changed, 1 added, 1 description edited
    What changed in the outcomes
    • AddedNumber of Participants with Adverse Events (AEs)Time frame: Up to approximately Day 141
    • Time frameEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraineWeek 9 to Week 12 → Up to approximately Week 12
    • DescriptionEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine: how it is measured was reworded
    Secondary outcomes 6 time frame changed, 4 description edited
    What changed in the outcomes
    • Time frameEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine as proportion of patientsWeek 9 to Week 12 → Up to approximately Week 12
    • Time frameEffect of repeat doses of MEDI0618 on disability caused by migraine headachesDay 1 to Day 85 and to Day 141 → Up to approximately Day 141
    • Time frameEffect of repeat doses of MEDI0618 on disability caused by migraine headaches#2Day 1, Day 29, Day 57 and Day 85 and to Day 141 → Up to approximately Day 141
    • Time frameEffect of repeat doses of MEDI0618 on the severity of migraine headachesWeek 9 to Week 12 → Up to approximately Week 12
    • Time frameEffect of repeat doses of MEDI0618 on the severity of migraine headaches#2Week 9 to Week 12 → Up to approximately Week 12
    • Time frameEffect of repeat doses of MEDI0618 on the severity of migraine headaches#3Week 9 to Week 12 → Up to approximately Week 12
    • DescriptionEffect of repeat doses of MEDI0618 on the severity of migraine headaches: how it is measured was reworded
    • DescriptionEffect of repeat doses of MEDI0618 on the severity of migraine headaches#2: how it is measured was reworded
    • DescriptionEffect of repeat doses of MEDI0618 on the severity of migraine headaches#3: how it is measured was reworded
    • DescriptionEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine as proportion of patients: how it is measured was reworded
    + 6 other changes: identifiers, verification date, description, design details, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06602479
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 7, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MEDI0618

Start the discussion